KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Cash & Equivalents (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Cash & Equivalents data on record, last reported at $213.8 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 712466.67% year-over-year to $213.8 million; the TTM value through Dec 2025 reached $213.8 million, up 712466.67%, while the annual FY2025 figure was $213.8 million, 712466.67% up from the prior year.
  • Cash & Equivalents reached $213.8 million in Q4 2025 per CRL's latest filing, up from $207.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $465.4 million in Q1 2021 and bottomed at $30000.0 in Q4 2024.
  • Average Cash & Equivalents over 5 years is $208.8 million, with a median of $210.2 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: crashed 99.99% in 2024, then soared 712466.67% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $4.0 million in 2021, then skyrocketed by 5714.37% to $233.9 million in 2022, then grew by 18.32% to $276.8 million in 2023, then plummeted by 99.99% to $30000.0 in 2024, then skyrocketed by 712466.67% to $213.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $213.8 million in Q4 2025, $207.1 million in Q3 2025, and $182.8 million in Q2 2025.